Relaxing of regulations for regenerative medicines has cascading effect internationally, new research warns
Researchers warn that if just one country decides to relax regulations in the field, a heightened sense of competition can spur others to do the same.
It’s unclear whether this deregulation best serves competition, science or the patients.
Regenerative medicine focuses on developing therapies to regenerate or replace injured, diseased or defective cells, tissues or organs, like stem cell ‘treatments’.
Due to the use of living cells, it can be hard to set regulations in the same way as for other drugs so differences in the rules can occur.
But, according to Professor Margaret Sleeboom-Faulkner from the University of Sussex and Douglas Sipp, from the RIKEN Centre for Developmental Biology (CDB), Kobe, Japan, one thing that should always be maintained is efficacy – the ability to reliably produce a certain therapeutic result.
Professor of Social & Medical Anthropology, Margaret Sleeboom-Faulkner said: “Regenerative medicine contains a lot of economic promise, and there’s already been enormous investments into it.”
“While this is good in terms of focusing on new and innovative treatments to improve healthcare, it also leaves the field particularly vulnerable to regulatory brokerage. When one country relaxes their regulations, others are tempted to do the same in order to ‘keep up’.”
“Competition is the last way we want medicine to be progressing.”
The paper, published today in the journal Science, uses the example of South Korea as the first country to give preferential regulatory treatment to stem cell medicine. Their decision to issue a flurry of three stem cell-based medical products between 2011-12, and a fourth in 2014, attracted international scepticism for sacrificing clinical data standards in exchange for speed to market.
Yet Japan, who had launched a multi-billion dollar initiative to lead the world in regenerative medicine, began to see South Korea as a competitor. This resulted in a change of Japanese law in 2013, to allow regenerative medicine products a faster entry to the market.
Professor Sleeboom-Faulkner explained: “The International Society for Stem Cell Research has published general guidelines around regenerative medicines but countries regulate it in different ways.”
“At the moment, Britain has the safety net of the EU stamp on its regulations. While we’re not expecting to lose that, with Brexit looming we could see new interpretations of the existing guidelines and find ourselves starting to compete with other countries too.
“The UK has a reputation for high standards in medicine regulation and should continue to uphold this and be vigilant in the face of political pressures for eye-catching innovation.”
Professor Sleeboom-Faulkner also notes that strict regulations can have a negative impact too, making things hard for developing countries who have to import equipment and resources. As a result, strict regulations can cause some lower income countries to relax the implementation of their regulations and take measures to be able to catch up. Of late, however, it is the wealthy countries that have become more permissive.
Professor Sleeboom-Faulkner said: “What’s needed is a greater awareness that the regulations of one country can have cascading effects internationally.
“Regenerative medicines are often trialled on patients with a terminal illness, so it’s hard to know the precise effect of all of this. With less stringent clinical trials and the fast-tracking of ‘treatment’, we’d assume standards are slipping and risks increase, but it’s hard to prove that.”
“Ideally, regulations should be internationally coordinated and there should be a collaborative global approach in order to maintain basic standards.”
Professor Sleeboom-Faulkner is urging countries to be cautious when it comes to developing treatments particularly in the face of deviant ventures such as the recent case of gene-edited foetuses in China, and the current trend of increasing flexibilities in regulations internationally.
The Latest on: Regenerative medicine regulation
via Google News
The Latest on: Regenerative medicine regulation
- CollPlant CEO Yehiel Tal Appointed to Serve on International Society for Biofabrication's Industry Relations Committeeon October 22, 2019 at 5:08 pm
regulation, and commercialization - CollPlant delivered a poster presentation at International Conference on Biofabrication in Columbus, Ohio on October 21, 2019 REHOVOT, Israel, Oct. 22, 2019 ...
- Dr. Peggy Goodell elected to National Academy of Medicineon October 21, 2019 at 10:48 am
D.C. “Dr. Goodell’s long career in regenerative medicine proves she is well-deserving of this distinction,” said Dr. Paul Klotman, president, CEO and executive dean of Baylor. “She is a renowned ...
- Japan altering regulations to approve practical regenerative medicine in 5 to 7 years instead of 10 yearson October 13, 2019 at 5:00 pm
SpaceX Will Use Tesla Car Batteries to Power Movable Wings for Starship Re-Entry Graphene Terahertz Telescopes Will be Thousands of Times Better Than Current Thz Telescopes ...
- Breakthrough in sex-chromosome regulationon October 3, 2019 at 8:57 am
According to the researchers, the findings represent a breakthrough in understanding sex-chromosome gene regulation. Understanding these chromosome-wide mechanisms could also be important in the field ...
- Breakthrough in sex-chromosome regulationon October 3, 2019 at 8:02 am
the findings represent a breakthrough in understanding sex-chromosome gene regulation. Understanding these chromosome-wide mechanisms could also be important in the field of regenerative medicine ...
- AIVITA Biomedical to Present at Meeting on the Mesa and Other Investor, Oncology and Regenerative Medicine Conferences in Octoberon October 1, 2019 at 5:49 am
AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the ...
- FDAnews Announces -- Regenerative Medicine and...on September 2, 2019 at 9:11 pm
Confused about the FDA's regenerative medicine and stem cell therapies regulations? This webinar will explain FDA's regulations and enforcement, and how stem cell stakeholders (pharma/biotech ...
- Relaxing of regulations for regenerative medicines has cascading effect internationallyon August 15, 2019 at 11:01 am
Regenerative medicine focuses on developing therapies to regenerate or replace injured, diseased or defective cells, tissues or organs, like stem cell 'treatments'. Due to the use of living cells, it ...
- Pursuing a Path of Regulatory Rigor: Taking Medtech, Regenerative Medicine to the Next Levelon August 14, 2019 at 7:18 am
The medical device industry is facing a generational change in the regulation and validation of its products.
via Bing News